Clinical Trial News and Research RSS Feed - Clinical Trial News and Research

Experimental PET tracer can diagnose concussion-related brain degeneration in living person

Experimental PET tracer can diagnose concussion-related brain degeneration in living person

An experimental positron emission tomography (PET) tracer can effectively diagnose concussion-related brain degeneration while a person is still alive, according to a proof-of-concept study conducted at the Icahn School of Medicine at Mount Sinai and published September 27 in the journal Translational Psychiatry. [More]
Clinical study to test efficacy of different formulations of flu vaccine in heart failure patients

Clinical study to test efficacy of different formulations of flu vaccine in heart failure patients

Heart disease patients enrolled in a clinical trial - designed to test whether a stronger dose of the influenza vaccine can prevent death or hospitalization due to a heart attack, heart failure, stroke or pneumonia - have begun receiving their first flu shots in Toronto and Boston. [More]
Expectations of cancer patients may not match with actual results in phase I studies

Expectations of cancer patients may not match with actual results in phase I studies

In a study of cancer patients considering whether they should participate in phase I clinical trials, a high percentage were willing to participate after discussions with clinical staff, but nearly half thought that their tumors would shrink, which is much higher than what is realistically achieved. [More]
New ABT approach results in greater weight loss than gold standard treatment, study shows

New ABT approach results in greater weight loss than gold standard treatment, study shows

A new approach to weight loss called Acceptance-Based Behavioral Treatment (ABT) helped people lose more weight and keep it off longer than those who received only Standard Behavioral Treatment (SBT) - a typical treatment plan encouraging reduced caloric intake and increased physical activity - according to a new randomized controlled clinical trial. [More]
Increasing adoption of SBRT improves survival rates for older patients with early stage lung cancer

Increasing adoption of SBRT improves survival rates for older patients with early stage lung cancer

Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC) rose from roughly 40 to 60 percent over the past decade, concurrent with the increasing adoption of SBRT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Research shows degenerative diseases affecting the retina may be treatable with gene therapy

Research shows degenerative diseases affecting the retina may be treatable with gene therapy

Researchers have demonstrated the ability to deliver a fully functional copy of the CLN3 gene to stem cells of patients with juvenile NCL, an inherited neurodegenerative disease in which a mutation in the CLN3 gene causes early-onset severe central vision loss. [More]
High levels of dietary zinc increases susceptibility to Clostridium difficile infections

High levels of dietary zinc increases susceptibility to Clostridium difficile infections

Too much dietary zinc increases susceptibility to infection by Clostridium difficile - "C. diff" - the most common cause of hospital-acquired infections. [More]
Hyaluronidase enzyme may be effective treatment option for spasticity caused by neurological injury

Hyaluronidase enzyme may be effective treatment option for spasticity caused by neurological injury

A naturally occurring enzyme called hyaluronidase may be an effective alternative treatment for spasticity, or muscle stiffness, a disabling condition in people who have had a stroke or other brain injury. [More]
Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis announced today that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes. [More]
Precision medicine trial shows analysing person's DNA improves treatment options for cancer patients

Precision medicine trial shows analysing person's DNA improves treatment options for cancer patients

A clinical trial for types of advanced cancer is the first of its kind to show that precision medicine - or tailoring treatment for individual people - can slow down the time it takes for a tumour to grow back, according to research presented at the Molecular Analysis for Personalised Therapy (MAP) conference, today (Friday). [More]
New study to examine effectiveness of orally administered drug in treating stuttering

New study to examine effectiveness of orally administered drug in treating stuttering

Stuttering, an interruption in the flow of speech, affects about three million Americans. It begins most often in childhood, affecting four men for every woman. A precise cause of this complex communicative disorder is not known. [More]
JAK inhibitors may be first effective treatment for people with alopecia areata

JAK inhibitors may be first effective treatment for people with alopecia areata

Seventy-five percent of patients with moderate to severe alopecia areata—an autoimmune disease that causes patchy, and less frequently, total hair loss—had significant hair regrowth after treatment with ruxolitinib, reported researchers from Columbia University Medical Center. By the end of their treatment, average hair regrowth was 92 percent. [More]
Study data does not support benefits of testosterone supplementation in men with ‘low T’

Study data does not support benefits of testosterone supplementation in men with ‘low T’

The prescription of testosterone supplementation for cardiovascular health, sexual function, physical function, mood, or cognitive function in men with "low T" is not supported by clinical trials data, conclude researchers who describe a review of more than 200 clinical trials published Sept. 21 in PLOS One. [More]
CIRM approves $5.2 million for research on life-long treatment for rare childhood disease

CIRM approves $5.2 million for research on life-long treatment for rare childhood disease

Cystinosis is a rare disease that usually strikes children before they are two years old and can lead to end stage kidney failure before their tenth birthday. [More]
Novel immunotherapy shows promise against AML in clinical trial

Novel immunotherapy shows promise against AML in clinical trial

A new type of immunotherapy shows promise against cases of acute myeloid leukemia (AML) that recur after treatment or that never respond to therapy in the first place. [More]
Bile acid transporter inhibitors can prevent NASH in mice, study shows

Bile acid transporter inhibitors can prevent NASH in mice, study shows

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of Atlanta have shown. [More]
UofL researchers receive NIH funding to explore how environmental exposures influence health of children

UofL researchers receive NIH funding to explore how environmental exposures influence health of children

The National Institutes of Health today announced a team of researchers headed by Janice Sullivan, M.D., of the University of Louisville is among grant recipients nationwide receiving funding for a seven-year, multicenter initiative called Environmental influences on Child Health Outcomes. [More]

Researchers call for transparency of clinical trial data to give clear picture of new treatments

Researchers have called for greater transparency in the public release of clinical trial data after a study revealed significant under-reporting of side effects in medical treatments. [More]
ECTRIMS, EAN collaborate to develop new therapeutic guidelines for MS

ECTRIMS, EAN collaborate to develop new therapeutic guidelines for MS

The 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (MS) concluded today in London (September 14-17) and one of the late breaking sessions presented the Clinical Guideline on the pharmacological management of people with Multiple Sclerosis developed jointly by ECTRIMS and European Academy of Neurology (EAN). [More]
New partnership between BetterYou and University of Sheffield paves way for vitamin D research

New partnership between BetterYou and University of Sheffield paves way for vitamin D research

A new collaboration between health pioneers BetterYou and scientists from the University of Sheffield, is paving the way for a three-year clinical trial looking at the effect of vitamin D supplementation on the quality of life of people with Irritable Bowel Syndrome (IBS). [More]
Advertisement
Advertisement